Advertisement
Screener

PUMA BIOTECHNOLOGY, INC. (PBYI) Number of Operating Segments

2.8 / 5 stars · 68/120 Roast Me

PUMA BIOTECHNOLOGY, INC. Number of Operating Segments

PUMA BIOTECHNOLOGY, INC. (PBYI) reported Number of Operating Segments of 100.00% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.

Financial Statements › Notes › Segment Reporting

us-gaap:NumberOfOperatingSegments · last filed 2025-11-06

  • PUMA BIOTECHNOLOGY, INC. number of operating segments for the quarter ending 2021-03-31 was 1.00 Segment, a 0.00% change year-over-year.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for the quarter ending 2020-03-31 was 1.00 Segment, a 0.00% change year-over-year.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for the quarter ending 2019-03-31 was 1.00 Segment, a 0.00% change year-over-year.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for the quarter ending 2018-03-31 was 1.00 Segment.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for fiscal 2020 was 1.00 Segment, a 0.00% change from fiscal 2019.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for fiscal 2019 was 1.00 Segment, a 0.00% change from fiscal 2018.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for fiscal 2018 was 1.00 Segment, a 0.00% change from fiscal 2017.
  • PUMA BIOTECHNOLOGY, INC. number of operating segments for fiscal 2017 was 1.00 Segment.

Segment

Period endNumber of Operating Segments 3 monthNumber of Operating Segments 6 monthNumber of Operating Segments 9 monthNumber of Operating Segments 12 month
2021-06-301.00 Segment
10-Q · filed 2021-08-05
2021-03-311.00 Segment
10-Q · filed 2021-05-06
2020-12-311.00 Segment
10-K · filed 2021-03-01
2020-09-301.00 Segment
10-Q · filed 2020-11-05
2020-06-301.00 Segment
10-Q · filed 2020-08-06
2020-03-311.00 Segment
10-Q · filed 2020-05-07
2019-12-311.00 Segment
10-K · filed 2020-02-28
2019-09-301.00 Segment
10-Q · filed 2019-11-07
2019-06-301.00 Segment
10-Q · filed 2019-08-09
2019-03-311.00 Segment
10-Q · filed 2019-05-10
2018-12-311.00 Segment
10-K · filed 2019-03-01
2018-09-301.00 Segment
10-Q · filed 2018-11-05
2018-06-301.00 Segment
10-Q · filed 2018-08-09
2018-03-311.00 Segment
10-Q · filed 2018-05-10
2017-12-311.00 Segment
10-K · filed 2018-03-09

pure

Period endNumber of Operating Segments 3 monthNumber of Operating Segments 6 monthNumber of Operating Segments 9 monthNumber of Operating Segments 12 month
2025-09-30100.00%
10-Q · filed 2025-11-06
2025-06-30100.00%
10-Q · filed 2025-08-07
2025-03-31100.00%
10-Q · filed 2025-05-08
2024-12-31100.00%
10-K · filed 2025-02-27
2024-09-30100.00%
10-Q · filed 2024-11-07
2024-06-30100.00%
10-Q · filed 2024-08-01
2024-03-31100.00%
10-Q · filed 2024-05-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARVINAS, INC. (ARVN)United States$0.510B58.38
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Evolus, Inc. (EOLS)United States$0.519B-13.32
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76